Skip to Main Content
Skip Nav Destination
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Emil Kraepelin, the founder of modern psychiatric classification, and the Nobel laureate Julius Wagner von Jauregg highlighted the role of infections and the immune system in psychiatric disorders. It is well known that infections can trigger various psychiatric syndromes and influence the course of psychiatric disorders. Psychiatric symptoms during virulent infections, often presenting as encephalitis or meningitis, normally are diagnosed as mental disorders due to a general medical condition. On the other hand, an expanding research field underpins the view that infections and activation of the immune system may play a causative role in major psychiatric disorders such as schizophrenia or major depression. Also in other psychiatric syndromes, such as Tourette's syndrome, inflammation - partially based on infections - is involved. For this mild smoldering inflammatory process, the ‘mild (chronic) encephalitis' concept was developed. In this chapter, findings related to immune activation and inflammation in schizophrenia, major depression and Tourette's syndromes as examples for this concept are described. Moreover, encouraging results from randomized clinical trials in schizophrenia and major depression showing a benefit of anti-inflammatory therapy in these psychiatric disorders are discussed as examples for immunomodulating treatment approaches in psychiatric disorders. Further immunotherapies used in Tourette's syndrome or pediatric autoimmune disorders associated with streptococci are highlighted as further examples for such a therapeutic approach.

Humans are constantly being assaulted by infectious agents. Fortunately, we have evolved a complex process, the immune response, to help fight and clear infection [1]. The immune response evoked by an infectious agent may or may not generate clinical symptoms, depending on the exact type and degree of response. Infectious diseases are well known to provoke psychiatric symptoms. As early as 1890, Emil Kraepelin, one of the founders of modern psychiatry, described during an influenza epidemic 11 cases of psychiatric disorders that presented with different symptoms such as depressed mood, a paranoid and hallucinatory syndrome, involuntary movements, cognitive deterioration, and a delirious state [2]. Later, Kraepelin postulated in his programmatic essay ‘Objectives and methods of psychiatric research' to make the immunological defense and adaption system a focus of psychiatric research [3,4]. There are also numerous descriptions of an association between chronic inflammation of the central nervous system (CNS) and psychopathological states [5]. For example, symptoms of depression and schizophrenia have been described in a certain form of multiple sclerosis [6]. The same is true for viral CNS infection with herpes simplex virus types 1 [7] and 2 [8,9] and measles [10]. Autoimmune processes, such as poststreptococcal disorders, lupus erythematodes and scleroderma, may present primarily as a psychopathological syndrome [11,12,13,14,15,16,17,18]. This line of evidence led to the concept of ‘mild encephalitis' [19].

In modern diagnostics, psychiatric symptoms coexisting with severe infections are diagnosed as ‘mental disorders due to a general medical condition'. Infections can cause a broad spectrum of psychiatric symptoms, e.g. delirium, psychotic disorder or mood disorder (table 1) [20].

Table 1

Diagnostic criteria DSM-IV: psychopathological states due to a general medical condition

Diagnostic criteria DSM-IV: psychopathological states due to a general medical condition
Diagnostic criteria DSM-IV: psychopathological states due to a general medical condition

Factors influencing the psychiatric presentation of infections are the subject of intense research and might include the pathogen, individual medical history and locus of infection. Infections of the CNS, such as meningitis and encephalitis, are believed to be more commonly associated with psychiatric symptoms than those of the peripheral organs, although peripheral infections are also well known to cause psychiatric disturbances. An example is ‘sickness behavior' as a model for depressive disorder, as described below.

‘Sickness behavior', the reaction of an organism to infection and inflammation, is well established as a model for depression in animals and humans [21,22]. The model is based on the observation that increased levels of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), are associated with depressive-like behavior in animals, including decreased drive and motivation, lack of energy and appetite, tiredness, and weight loss. The involvement of cytokines in the regulation of sickness behavior in humans has been studied by administering the bacterial endotoxin lipopolysaccharide to healthy volunteers [23]. Levels of anxiety, depression and cognitive impairment were found to be related to the levels of circulating cytokines [23,24].

The findings of these studies, together with the sickness behavior model, have led to the hypothesis that ‘cytokines sing the blues', i.e. cytokines and a proinflammatory immune state are involved in the pathogenesis of major depression [25,26]. This view is supported by recent literature showing signs of a proinflammatory immune state in major depression.

The innate immune system, which includes natural killer cells and monocytes, for example, as the first barrier against infection, is phylogenetically the oldest part of the immune system. The adaptive immune response with the antibody-producing B lymphocytes and the T lymphocytes (helper T cells) is the pathogen- and antigen-specific component of the immune system. Cytokines regulate all cellular components of the immune system and are involved in both the innate and the adaptive immune response. Helper T cells are of two types: T helper 1 (Th-1) and 2 (Th-2). Th-1 cells produce the characteristic ‘type 1' activating cytokines such as IL-2 and interferon-γ. However, since not only Th-1 cells, but also certain monocytes/macrophages (M1) and other cell types, produce these cytokines, this type of immune response is called the type 1 immune response. The humoral, antibody-producing arm of the adaptive immune system is mainly activated by the type 2 immune response. Th-2 and certain monocytes/macrophages (M2) produce mainly IL-4, IL-10 and IL-13 [27]. Another terminology system differentiates cytokines as being proinflammatory and anti-inflammatory. Proinflammatory cytokines such as TNF-α and IL-6 are primarily secreted from monocytes and macrophages, and activate other cellular components of the inflammatory response. While TNF-α mainly activates the type 1 response, IL-6 activates the type 2 response, including antibody production. Anti-inflammatory cytokines such as IL-4 and IL-10 help to downregulate the inflammatory immune response (table 2).

Table 2

Components of the innate and adaptive immune system

Components of the innate and adaptive immune system
Components of the innate and adaptive immune system

Elevated plasma concentrations of C-reactive protein (CRP) are a common marker of an inflammatory process. CRP levels have been repeatedly observed to be higher in people with depression than in healthy controls, for example in severely depressed in-patients [28], and high CRP levels have been found to be associated with the severity of depression [29]. Higher CRP levels have also been found in both men [30,31] and women [32,33] in remission after a depressive state. In a sample of older healthy persons, CRP levels and IL-6 levels were predictive of cognitive symptoms of depression 12 years later [34]. In comparison to acute inflammatory diseases, such as pneumonia, however, the CRP increase is slight.

Characteristics of immune activation in major depression include increased numbers of circulating lymphocytes and phagocytic cells, upregulated serum levels of markers of immune activation, higher serum concentrations of positive acute phase proteins coupled with reduced levels of negative acute phase proteins, and increased release of proinflammatory cytokines such as IL-1β, IL-2, TNF-α and IL-6 (through activated macrophages) and interferon-γ (through activated T cells) [35,36,37,38,39,40,41]. Interferon-α is well documented to induce severe depressive symptoms, including suicidality, in about one third of patients [42]. Different research groups [43,44,45] have described increased numbers of peripheral mononuclear cells in major depression, and, in accordance with findings of increased monocytes and macrophages, an increased level of neopterin, a marker for activated macrophages, has also been described [46,47,48,49]. The role of cellular immunity, cytokines, and the innate and adaptive immune systems in depression has been recently reviewed [50,51]. Table 3 summarizes several examples for immune markers in major depression.

Table 3

Examples for immune markers reflecting immune activation in major depression

Examples for immune markers reflecting immune activation in major depression
Examples for immune markers reflecting immune activation in major depression

Although immune activation is well established in major depression and infections are well known to trigger depressive symptoms, the association between infection and major depression has not been properly studied. In contrast, the etiology of immune activation in major depression is the subject of intense research.

The results of a prospective population-based Danish register study in 3.6 million people born between 1945 and 1996 support the view that an infection or autoimmune disease significantly increases the risk of a depressive disorder. Participants were followed up from 1977 to 2010, for a total of 78 million person-years. All people diagnosed with an affective disorder according to ICD-8, ICD-9 or ICD-10 and at least one in- or outpatient hospital contact due to an affective disorder (including bipolar disorder) were included. Every previous hospital contact due to an autoimmune disorder or infection (apart from HIV/AIDS) was then recorded. Over 91,000 cases of affective disorder were identified, of which approximately 30,000 had previously been diagnosed with infection and >4,000 with an autoimmune disease. The results show that hospitalization for infection significantly increased the risk for later mood disorder by 63% [incidence rate ratio (IRR) 1.63 (95% CI: 1.61-1.66)] and hospitalization for autoimmune disease significantly increased it by 45% [IRR 1.45 (95% CI: 1.39-1.52)]. Both risk factors interacted and increased the risk to an IRR of 2.35 (95% CI: 2.25-2.46). The findings do not support the hypothesis that primarily CNS infections result in later symptoms of mood disorders as, for example, the risks were higher for hepatitis infection [IRR 2.82 (95% CI: 2.58-3.08)] than for sepsis or CNS infections. Interestingly, the risk for mood disorder increased with the proximity of time to the infection, with the highest risk within the first year [IRR 2.70 (95% CI: 2.60-2.80)] [52]. Since only infections and autoimmune disorders resulting in a hospital contact were recorded, the risk for a mood disorder might be higher when all infections are considered.

There are numerous descriptions of an association between (chronic) inflammation of the CNS and schizophrenia [5]. For example, symptoms of schizophrenia have been described in the encephalitic form of multiple sclerosis [6], in viral CNS infection with herpes simplex virus types 1 [7] and 2 [8], and measles [10], and also in autoimmune processes such as poststreptococcal disorders [11,12,13,14], lupus erythematodes and scleroderma [15,16,17,18]. Schizophreniform symptoms in primary infectious diseases are diagnosed according to DSM-IV as a mental disorder due to a general medical condition (whereas in earlier times the diagnosis was ‘organic brain disorder'). However, we do not know whether schizophreniform symptoms are ‘secondary' to an infection or autoimmune process or the infection is a comorbid condition in a person with a ‘primary' diagnosis of schizophrenia.

Signs of inflammatory degradation products have been described in schizophrenic brain tissue [53] and in the cerebrospinal fluid of about 50% of people with schizophrenia [54]. Furthermore, a blunted type 1 and (compensatory) increased type 2 cytokine pattern have been repeatedly observed in people with unmedicated schizophrenia [55]. Recently published reviews on the imbalance of types 1 and 2 and pro- and anti-inflammatory immune systems as well as innate immunity, including the monocytic system, in schizophrenia have indicated that an inflammatory process plays an important role in the pathophysiology of (at least) a subgroup of people with schizophrenia [56,57].

Over the last five decades, research on the neurobiology of schizophrenia has focused overwhelmingly on disturbances of dopaminergic neurotransmission [58]. A disturbance of the dopamine system is clearly involved in the pathogenesis of schizophrenia, although the mechanism is unclear and antipsychotic antidopaminergic drugs still show unsatisfactory therapeutic effects.

IL-1β, which can induce the conversion of rat mesencephalic progenitor cells into a dopaminergic phenotype [59,60,61], and IL-6, which is highly effective in decreasing the survival of fetal brain serotonergic neurons [62], seem to have an important effect on the development of the neurotransmitter systems specifically involved in schizophrenia, although the specificity of these cytokines is a matter of discussion. Maternal immune stimulation during pregnancy increased the number of mesencephalic dopaminergic neurons in the fetal brain, and the increase was probably associated with a dopaminergic excess in the midbrain [63]. Persistent pathogens might be key factors that drive imbalances of the immune reaction [18]. Nevertheless, many questions remain unanswered about how immunity and immune pathology in virus infections interact in order to show clinical symptoms [64].

Much evidence indicates that a lack of glutamatergic neurotransmission, mediated via NMDA antagonism, is a key mechanism in the pathophysiology of schizophrenia [65]. Kynurenic acid, the only NMDA receptor antagonist known to occur naturally in the human CNS [66], is one of at least three neuroactive intermediate products of the kynurenine pathway. In schizophrenia, a predominant type 2 immune response inhibits the enzyme indoleamine 2,3-dioxygenase, resulting in an increased production of kynurenic acid and consequently in NMDA receptor antagonism [65,67]. The recent finding of NMDA receptor antibodies in about 10% of patients with acute and unmedicated schizophrenia is especially interesting in this regard (fig. 1).

Fig. 1

The enzyme indoleamine 2,3-dioxygenase (IDO) is activated by proinflammatory cytokines [and prostaglandin E2 (PGE2)] and inhibited by anti-inflammatory cytokines. IDO degrades kynurenine, serotonin and melatonin, and influences the concentrations of these neuroactive metabolites and neurotransmitters. The enzyme KMO [kynurenine 3-monooxygenase (identical with kynurenine 3-hydroxylase)] drives the metabolism to the neurotoxic metabolite quinolinic acid. The enzyme KAT (kynurenine aminotransferase) drives the metabolism to kynurenic acid.

Fig. 1

The enzyme indoleamine 2,3-dioxygenase (IDO) is activated by proinflammatory cytokines [and prostaglandin E2 (PGE2)] and inhibited by anti-inflammatory cytokines. IDO degrades kynurenine, serotonin and melatonin, and influences the concentrations of these neuroactive metabolites and neurotransmitters. The enzyme KMO [kynurenine 3-monooxygenase (identical with kynurenine 3-hydroxylase)] drives the metabolism to the neurotoxic metabolite quinolinic acid. The enzyme KAT (kynurenine aminotransferase) drives the metabolism to kynurenic acid.

Close modal

Findings regarding kynurenic acid in schizophrenia vary. Elevated kynurenic acid has mainly been described in the cerebrospinal fluid [68,69,70] and in the brains of people with schizophrenia [71,72], as well as in animal models of schizophrenia [73]. However, no increased kynurenic acid levels have been described in the peripheral blood of people with first-episode schizophrenia [74] or in other groups of people with schizophrenia [75]. Increased neopterin values are to be mentioned here again [76]. Antipsychotic medication, however, affects kynurenine metabolites and has to be regarded as an interfering variable [74,75,77].

The proposed involvement of immune activation and inflammation in the pathogenesis of schizophrenia has led to the hypothesis that infectious agents may be involved. Many recent studies have focused on members of the virus family of Herpesviridae [78], Borna virus [79], intracellular bacteria like Chlamydia[80] and the protozoan organism Toxoplasma gondii[81]. The roles of Cytomegalovirus and T. gondii have been stressed for many years [82]. These agents are the focus of research because of their ability to establish persistent infections within the CNS and the occurrence of neurological and psychiatric symptoms in some individuals infected with these agents [83].

The group of Danish researchers mentioned above performed a study in schizophrenia similar to their study in affective disorders [127]. They found that severe infections and autoimmune disorders also additively increased the risk of schizophrenia and schizophrenia spectrum disorders. However, this large-scale study did not confirm infections in the parents, including intrauterine infections, as definite risk factors. Despite its large scale, the study's sensitivity was not very high because only infections associated with a contact to a Danish hospital were recorded, meaning that the risk factors which were identified may only have been the ‘tip of the iceberg'.

Animal models of schizophrenia show that stimulation of the maternal immune system by viral agents leads to typical symptoms in the offspring. Evidence for pre- or perinatal exposure to infections as a risk factor for schizophrenia has been obtained not only from animal models, but also from studies with various viruses in humans. Increased risk for schizophrenia in the offspring was also observed after respiratory infections or genital or reproductive tract infections. T. gondii infection in mothers was also described to be a risk factor. Interestingly, recent animal research showed that stressful events in later stages of life (during puberty, an especially vulnerable phase in life) unmask latent neuropathological consequences of prenatal immune activation [84]. This animal model might explain the delay between an early inflammation and the onset of schizophrenia years later.

Both infections before birth and infections, particularly of the CNS, during later stages of brain development increase the risk for later schizophrenia. Antibody titers against viruses have been examined in the sera of people with schizophrenia for many years, but the results have been inconsistent due to reasons such as interfering factors not being controlled for. Antibody levels are associated with the medication state, a finding which partly explains earlier controversial results. In one of our own studies, people with schizophrenia had higher titers of different pathogens than controls, a phenomenon that we call the ‘infectious index'.

Prenatal immune activation - regardless of whether it is triggered by infection - is an important risk factor for schizophrenia. In humans, increased maternal levels of the proinflammatory cytokine IL-8 during pregnancy were shown to increase the risk for schizophrenia in the offspring, whatever the reason for the increase in IL-8. Moreover, increased maternal IL-8 levels in pregnancy were also significantly related to decreased brain volume, leading to lower volumes of the right posterior cingulum and the left entorhinal cortex, and higher volumes of the ventricles in the offspring with schizophrenia (fig. 2).

Fig. 2

Pathoetiological model of psychiatric disorders with special emphasis on the influence of infections, inflammation and the immune system. Besides other environmental factors such as stress (chronic stress depletes the immune response), pathogens are an important factor. Immune genes are involved in psychiatric disorders. The activation or inhibition of the immune response influences the noradrenergic, serotonergic, dopaminergic and glutamatergic neurotransmission and the (neuroprotective and/or neurotoxic) tryptophan/kynurenine system, and through these mechanisms contributes to the psychopathology of psychiatric disorders. Anti-inflammatory drugs show beneficial effects in disorders such as schizophrenia or major depression.

Fig. 2

Pathoetiological model of psychiatric disorders with special emphasis on the influence of infections, inflammation and the immune system. Besides other environmental factors such as stress (chronic stress depletes the immune response), pathogens are an important factor. Immune genes are involved in psychiatric disorders. The activation or inhibition of the immune response influences the noradrenergic, serotonergic, dopaminergic and glutamatergic neurotransmission and the (neuroprotective and/or neurotoxic) tryptophan/kynurenine system, and through these mechanisms contributes to the psychopathology of psychiatric disorders. Anti-inflammatory drugs show beneficial effects in disorders such as schizophrenia or major depression.

Close modal

An immune-based therapeutic approach for psychiatric disorders was first proposed decades ago when the Nobel laureate Julius Wagner von Jauregg developed a vaccination therapy for psychoses [85]. He treated patients successfully with vaccines derived from attenuated Mycobacteriumtuberculosis, Plasmodium malariae or Salmonella Typhi, all of which stimulate a type 1 immune response [86]. This therapy showed the best results in syphilis infection, but Wagner von Jauregg also administered the vaccination therapy for other psychiatric disorders. After the introduction of penicillin and as a consequence of the overwhelming success of the neurotransmitter approach in psychiatry, the therapeutic vaccination approach was not pursued further. In the past decade, the emerging limitations of the neurotransmitter approach for pathogenetic research have resulted in increased interest in other therapeutic approaches, including the possible use of modern anti-inflammatory agents in schizophrenia [87]. The cyclooxygenase-2 (COX-2) inhibitor celecoxib was studied as an add-on to risperidone in a prospective, randomized, double-blind study of acute exacerbation of schizophrenia; patients receiving celecoxib had a statistically significant better outcome and showed an increase in the type 1 immune response [88]. The clinical effects of COX-2 inhibition in schizophrenia are especially pronounced in cognition [89]. The efficacy of therapy with a COX-2 inhibitor seems most pronounced in the first years of the schizophrenia disease process [90,91]. A recent study also found a beneficial effect of acetylsalicylic acid in schizophrenia spectrum disorders [92]. A recent meta-analysis on the use of nonsteroidal anti-inflammatory drugs in schizophrenia found a significant benefit of add-on treatment with nonsteroidal anti-inflammatory drugs on positive and negative symptoms and on the total symptomatology over all studies [93]. A second meta-analysis on the same topic, but based on a broader database, found a benefit only in the early stages of the disease, in particular in first manifestations of schizophrenia [94].

COX-2 inhibitors also showed interesting effects in animal models of depression. Treatment with the COX-2 inhibitor celecoxib, but not with a COX-1 inhibitor, prevented the dysregulation of the hypothalamic-pituitary-adrenal axis, in particular the increase of cortisol, one of the key biological features associated with depression [95,96]. This effect was expected because prostaglandin E2, which stimulates the hypothalamic-pituitary-adrenal axis in the CNS [97], is inhibited by COX-2 inhibition. The functional effects of IL-1 in the CNS, which include sickness behavior, were also shown to be antagonized by treatment with a selective COX-2 inhibitor [98].

COX-2 inhibitors also affect the CNS serotonergic system, either directly or via CNS immune mechanisms. In a rat model, treatment with rofecoxib was followed by an increase of serotonin in the frontal and temporoparietal cortex [99]. COX-2 inhibitors would be expected to show a clinical antidepressant effect since a lack of serotonin is one of the main factors in the pathophysiology of depression. The antidepressant action of COX-2 inhibitors may be mediated through inhibition of IL-1 and IL-6 release. In the depression model of bulbectomized rats, a decrease in hypothalamus cytokine levels and a change in behavior have been observed after chronic celecoxib treatment [100]. In another animal model of depression, however, the mixed COX-1/COX-2 inhibitor acetylsalicylic acid showed an additional antidepressant effect by accelerating the antidepressant effect of fluoxetine [101]. In an open-label pilot study in humans, acetylsalicylic acid also accelerated the antidepressant effect of fluoxetine and increased the response rate to monotherapy with fluoxetine in depressed nonresponders [102]. A significant therapeutic effect of the COX-2 inhibitor celecoxib in major depression was also found in a randomized, double-blind pilot add-on study [103]. Another randomized, double-blind study in 50 patients with major depression also showed a significantly better outcome with the COX-2 inhibitor celecoxib plus fluoxetine than with fluoxetine alone [104]. A similar result was obtained with a celecoxib add-on approach to sertraline in major depression [105,106]. A meta-analysis on the use of COX-2 inhibitors in major depression found an overall benefit of celecoxib add-on therapy [107].

Interestingly, etanercept, which blocks the interaction of TNF-α with the TNF-α cell surface receptors, showed a highly significant antidepressant effect [108]. A study with another TNF-α receptor blocker, infliximab, found no overall benefit in treatment-resistant patients with major depression, but did find a benefit in those with higher levels of inflammatory markers, such as CRP, TNF-α or soluble TNF receptors [106].

Although those preliminary data have to be interpreted cautiously and further research is needed to evaluate the therapeutic effects of COX-2 inhibitors in major depression, the results are encouraging for further studies on the inflammatory hypothesis of depression and the pathogenesis, course and therapy of the disease.

Maternal infection during pregnancy and childhood infections are risk factors for later schizophrenia, especially in combination with stress during puberty [84,109]. Furthermore, infections in later life are risk factors for both major depression [52] and schizophrenia [110]. In major depression, an inflammatory process seems to play a role in a subgroup of patients, but no specific infectious pathogens have been described. Stress and other environmental factors may contribute to the proinflammatory state. For example, animal models indicate that early life separation is associated with increased cytokine levels and passive behavior [111] and that early childhood stress disrupts the regulation of innate immune resistance to a challenge (lipopolysaccharide, viral infection), resulting in enhanced immunological and behavioral responses to immune activation in animals [112]. In people with depression, early-life stress is associated with enhanced inflammatory responsiveness to stress [113]. Moreover, a relationship between early childhood stress, inflammatory markers and depression in adult patients has been described [114,115]. Overall, studies indicate that stress and adverse events in childhood seem to be risk factors for an inflammatory state in adulthood.

There are further examples for the involvement of infections in psychiatric disorders. Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) manifests with tics, Tourette's syndrome and/or obsessive-compulsive symptoms [116], and is a consequence of streptococcal infection. However, not only Streptococcus but also other infectious agents such as Borrelia burgdorferi[117] or Mycoplasma pneumoniae [118,119] may directly or indirectly cause this syndrome. Therefore, the concept of pediatric infection-triggered autoimmune neuropsychiatric disorder, a postinfectious syndrome not restricted to streptococcal infection, was introduced [116,120]. The broader concepts of pediatric acute-onset neuropsychiatric syndrome [121] and childhood acute neuropsychiatric syndromes, which define a much broader clinical spectrum encompassing etiologically diverse entities, were recently proposed to overcome the criticism that the postinfectious syndrome might present with behavioral symptoms or comorbidities other than tics and obsessive-compulsive symptoms. Exploratory studies aiming to identify clinical or cognitive features that could discriminate PANDAS from other pediatric obsessive-compulsive and tic disorders have presented methodological limitations and are therefore inconclusive. Given the uncertainties regarding the clinical definition of PANDAS, it is not surprising that the evidence for a postinfectious, immune-mediated pathophysiology has to be further elucidated and specified [122]. However, therapeutic studies based on the PANDAS concept have shown that immunomodulating therapies, such as intravenous γ-immunoglobulin or plasmapheresis, have highly significant advantages compared to placebo [123].

The conceptual and terminological heterogeneity discussed above reflects the difficulties not only of postinfectious (auto-)immune syndromes, but also of infection- and immune-mediated disorders in psychiatry in general: the pathophysiological process is not fully elucidated, specific mechanisms still need to be explored and further scientific efforts are necessary. On the other hand, similar to the neurotransmitter-centered biological approach in psychiatry in which therapies were developed first and biological explanations came later, effective therapeutic approaches are on the way and may provide post hoc validation of the discussed concepts.

The possible influences of infection and immune processes on the pathogenesis of major psychiatric disorders resulting in inflammation have long been neglected. Increasing evidence for a role of proinflammatory cytokines in major depression and schizophrenia, the strong influence of pro- and anti-inflammatory cytokines on the tryptophan/kynurenine metabolism and - related to that mechanism - the influence of cytokines on the glutamatergic neurotransmission support the view that infection, psychoneuroimmunology and inflammation rightly should be a focus of psychiatric research. This view is fostered by the results of (immuno-) genetic findings and the exhibited therapeutic effects of anti-inflammatory drugs in schizophrenia and major depression. On the other hand, it is possible that immunological research in patients may be susceptible to artefacts; interfering variables such as medication, smoking, stress, sleep and others play an important role and cannot always been controlled. This can be shown by the example of stress: stress is not only - according to the ‘vulnerability-stress-model' of schizophrenia - a condition sine qua non in schizophrenia, it is also a confounding factor for research of the immune system and inflammatory processes.

These considerations show that further research is needed to clarify the role of infection and of the immune system in psychiatric disorders. Recent results encourage placing further emphasis on this fascinating field. Therapeutic studies, including meta-analyses, support the view that therapeutic progress based on anti-inflammatory and/or immunomodulating approaches are not only of theoretical interest, but may have an important clinical impact and might lead to a paradigm change in psychiatric therapy.

1.
O'Neill LA: How frustration leads to inflammation. Science 2008;320:619-620.
2.
Kraepelin E: Über Psychosen nach Influenza. Dtsch Med Wochenschr 1890;11:209-212.
3.
Kraepelin E: Ziele und Wege der Psychiatrischen Forschung. Z Ges Neurol Psychiatrie 1918;42:169-205.
4.
Steinberg H, Himmerich H: Emil Kraepelin's habilitation and his thesis: a pioneer work for modern systematic reviews, psychoimmunological research and categories of psychiatric diseases. World J Biol Psychiatry 2013;14:248-257.
5.
Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Muller N, Kanchanatawan B, Maes M: Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:1-4.
6.
Felgenhauer K: Psychiatric disorders in the encephalitic form of multiple sclerosis. J Neurol 1990;237:11-18.
7.
Chiveri L, Sciacco M, Prelle A: Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. Eur Neurol 2003;50:182-183.
8.
Oommen KJ, Johnson PC, Ray CG: Herpes simplex type 2 virus encephalitis presenting as psychosis. Am J Med 1982;73:445-448.
9.
Fazekas C, Enzinger C, Wallner M, Kischka U, Greimel E, Kapeller P, Stix P, Pieringer W, Fazekas F: Depressive symptoms following herpes simplex encephalitis - an underestimated phenomenon? Gen Hosp Psychiatry 2006;28:403-407.
10.
Hiroshi H, Seiji K, Toshihiro K, Nobuo K: An adult case suspected of recurrent measles encephalitis with psychiatric symptoms (in Japanese). Seishin Shinkeigaku Zasshi 2003;105:1239-1246.
11.
Mercadante MT, Busatto GF, Lombroso PJ, Prado L, Rosario-Campos MC, do VR, Marques-Dias MJ, Kiss MH, Leckman JF, Miguel EC: The psychiatric symptoms of rheumatic fever. Am J Psychiatry 2000;157:2036-2038.
12.
Teixeira AL Jr, Maia DP, Cardoso F: Psychosis following acute Sydenham's chorea. Eur Child Adolesc Psychiatry 2007;16:67-69.
13.
Kerbeshian J, Burd L, Tait A: Chain reaction or time bomb: a neuropsychiatric-developmental/neurodevelopmental formulation of tourettisms, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS. World J Biol Psychiatry 2007;8:201-207.
14.
Bechter K, Bindl A, Horn M, Schreiner V: Therapy-resistant depression with fatigue. A case of presumed streptococcal-associated autoimmune disorder (in German). Nervenarzt 2007;78:338, 340-341.
15.
Müller N, Gizycki-Nienhaus B, Günther W, Meurer M: Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid. Biol Psychiatry 1992;31:1151-1156.
16.
Müller N, Gizycki-Nienhaus B, Botschev C, Meurer M: Cerebral involvement of scleroderma presenting as schizophrenia-like psychosis. Schizophr Res 1993;10:179-181.
17.
van Dam AP: Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991;11:1-11.
18.
Nikolich-Zugich J: Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 2008;8:512-522.
19.
Bechter K: Mild encephalitis underlying psychiatric disorders - a reconsideration and hypothesis exemplified on Borna disease. Neurol Psychiatry Brain Res 2001;9:55-70.
20.
American Psychiatric Association Diagnostic Criteria from DSM-IV. Washington, American Psychiatric Association, 1994.
21.
Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:7-24.
22.
Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
23.
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
24.
Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R: Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology 2002;27:945-956.
25.
Raison CL, Miller AH: Do cytokines really sing the blues? Cerebrum 2013;2013:10.
26.
Raison CL, Miller AH: The evolutionary significance of depression in pathogen host defense (PATHOS-D). Mol Psychiatry 2013;18:15-37.
27.
Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166-6173.
28.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-379.
29.
Häfner S, Baghai TC, Eser D, Schüle C, Rupprecht R, Bondy B, Bedarida G, von Schacky C: C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients. J Psychiatr Res 2008;42:163-165.
30.
Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. Psychosom Med 2003;65:347-356.
31.
Ford DE, Erlinger TP: Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004;164:1010-1014.
32.
Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O, Duncko R, Drevets WC, Manji HK, Charney DS, Gold PW, Neumeister A: Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 2007;62:309-313.
33.
Cizza G, Eskandari F, Coyle M, Krishnamurthy P, Wright EC, Mistry S, Csako G: Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. Horm Metab Res 2009;41:641-648.
34.
Gimeno D, Marmot MG, Singh-Manoux A: Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008;33:1322-1334.
35.
Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R: Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:713-730.
36.
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309.
37.
Maes M, Meltzer HY, Buckley P, Bosmans E: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995;244:325-329.
38.
Irwin M: Immune correlates of depression. Adv Exp Med Biol 1999;461:1-24.
39.
Nunes SO, Reiche EMV, Morimoto HK, Matsuo T, Itano EN, Xavier EC, Yamashita CM, Vieira VR, Menoli AV, Silva SS, Costa FB, Reiche FV, Silva FL, Kaminami MS: Immune and hormonal activity in adults suffering from depression. Braz J Med Biol Res 2002;35:581-587.
40.
Müller N, Schwarz MJ: Immunology in anxiety and depression; in Kasper S, den Boer JA, Sitsen JMA (eds): Handbook of Depression and Anxiety. New York, Marcel Dekker, 2002, pp 267-288.
41.
Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203-208.
42.
Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M: Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 2010;51:466-473.
43.
Herbert TB, Cohen S: Depression and immunity: a meta-analytic review. Psychol Bull 1993;113:472-486.
44.
Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996;94:198-204.
45.
Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H: Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 2001;251:90-97.
46.
Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC: Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res 1984;11:83-89.
47.
Dunbar PR, Hill J, Neale TJ, Mellsop GW: Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med 1992;22:1051-1057.
48.
Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche BV, Cosyns P: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994;54:143-160.
49.
Bonaccorso S, Lin AH, Verkerk R, Van Hunsel F, Libbrecht I, Scharpe S, DeClerck L, Biondi M, Janca A, Maes M: Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. J Affect Disord 1998;48:75-82.
50.
Müller N, Myint AM, Schwarz MJ: Inflammatory biomarkers and depression. Neurotox Res 2011;19:308-318.
51.
Maes M: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-675.
52.
Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, Mortensen PB: Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013;70:812-820.
53.
Körschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Müller N: Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 1996;19:103-109.
54.
Wildenauer DB, Körschenhausen D, Hoechtlen W, Ackenheil M, Kehl M, Lottspeich F: Analysis of cerebrospinal fluid from patients with psychiatric and neurological disorders by two-dimensional electrophoresis: identification of disease-associated polypeptides as fibrin fragments. Electrophoresis 1991;12:487-492.
55.
Schwarz MJ, Müller N, Riedel M, Ackenheil M: The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001;56:483-486.
56.
Müller N, Schwarz MJ: Immune system and schizophrenia. Curr Immunol Rev 2010;6:213-220.
57.
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-808.
58.
Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186.
59.
Ling ZD, Potter ED, Lipton JW, Carvey PM: Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 1998;149:411-423.
60.
Kabiersch A, Furukawa H, del RA, Besedovsky HO: Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann NY Acad Sci 1998;840:123-127.
61.
Potter ED, Ling ZD, Carvey PM: Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res 1999;296:235-246.
62.
Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH: Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 1997;15:711-716.
63.
Winter C, Djodari-Irani A, Sohr R, Morgenstern R, Feldon J, Juckel G, Meyer U: Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009;12:513-524.
64.
Rouse BT, Sehrawat S: Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 2010;10:514-526.
65.
Müller N, Schwarz MJ: The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm 2007;suppl 72:269-280.
66.
Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309-379.
67.
Müller N, Myint AM, Schwarz MJ: Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011;17:130-136.
68.
Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-98.
69.
Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S: Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005;80:315-322.
70.
Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S: Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012;38:426-432.
71.
Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001;50:521-530.
72.
Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R: Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011;37:1147-1156.
73.
Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L, Olsson E, Larsson K, Engberg G, Erhardt S: Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 2009;12:501-512.
74.
Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK: 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011;14:756-767.
75.
Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK: Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 2011;25:1576-1581.
76.
Kuehne LK, Reiber H, Bechter K, Hagberg L, Fuchs D: Cerebrospinal fluid neopterin is brain-derived and not associated with blood CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. J Psychiatr Res 2013;47:1417-1422.
77.
Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R: Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006;113:1355-1365.
78.
Hare EH, Price JS, Slater E: Schizophrenia and season of birth. Br J Psychiatry 1972;120:124-125.
79.
Machon RA, Mednick SA, Schulsinger F: The interaction of seasonality, place of birth, genetic risk and subsequent schizophrenia in a high risk sample. Br J Psychiatry 1983;143:383-388.
80.
Wright P, Takei N, Rifkin L, Murray RM: Maternal influenza, obstetric complications, and schizophrenia. Am J Psychiatry 1995;152:1714-1720.
81.
Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006;32:200-202.
82.
Torrey EF, Leweke MF, Schwarz MJ, Mueller N, Bachmann S, Schroeder J, Dickerson F, Yolken RH: Cytomegalovirus and schizophrenia. CNS Drugs 2006;20:879-885.
83.
Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M: Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 1998;18:349-351.
84.
Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R, Winter C, Riva MA, Mortensen PB, Schedlowski M, Meyer U: Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 2013;339:1095-1099.
85.
Wagner von Jauregg J: Fieberbehandlung bei Psychosen. Wien Med Wochenschr 1926;76:79-82.
86.
Müller N, Schwarz MJ, Riedel M: COX-2 inhibition in schizophrenia: focus on clinical effects of celecoxib therapy and the role of TNF-alpha; in Eaton WW (ed): Medical and Psychiatric Comorbidity over the Course of Life. Washington, American Psychiatric Publishing, 2005, pp 265-276.
87.
Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le GE, Marlinge E, Tamouza R, Leboyer M: Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 2014;129:163-179.
88.
Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-1034.
89.
Müller N, Riedel M, Schwarz MJ, Engel RR: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005;255:149-151.
90.
Müller N: COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 2010;11:31-42.
91.
Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M: Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:119-124.
92.
Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:520-527.
93.
Sommer IE, de WL, Begemann M, Kahn RS: Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012;73:414-419.
94.
Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU: Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013;39:1230-1241.
95.
Casolini P, Catalani A, Zuena AR, Angelucci L: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002;68:337-343.
96.
Hu F, Wang X, Pace TW, Wu H, Miller AH: Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry 2005;10:426-428.
97.
Song C, Leonard BE: Fundamentals of psychoneuroimmunology. Chicester, J Wiley and Sons, 2000.
98.
Cao C, Matsumura K, Ozaki M, Watanabe Y: Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J Neurosci 1999;19:716-725.
99.
Sandrini M, Vitale G, Pini LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res 2002;51:154-159.
100.
Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007;14:65-71.
101.
Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F, Kriwin P, Mendlewicz J: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006;21:219-225.
102.
Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006;21:227-231.
103.
Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.
104.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607-611.
105.
Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S: Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012;141:308-314.
106.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH: A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41.
107.
Na KS, Lee KJ, Lee JS, Cho YS, Jung HY: Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:79-85.
108.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
109.
Meyer U, Schwarz MJ, Müller N: Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011;132:96-110.
110.
Benros ME, Mortensen PB, Eaton WW: Autoimmune diseases and infections as risk factors for schizophrenia. Ann NY Acad Sci 2012;1262:56-66.
111.
Hennessy MB, Schiml-Webb PA, Miller EE, Maken DS, Bullinger KL, Deak T: Anti-inflammatory agents attenuate the passive responses of guinea pig pups: evidence for stress-induced sickness behavior during maternal separation. Psychoneuroendocrinology 2007;32:508-515.
112.
Avitsur R, Sheridan JF: Neonatal stress modulates sickness behavior. Brain Behav Immun 2009;23:977-985.
113.
Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM: Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-1633.
114.
Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I: Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry 2010;71:1007-1016.
115.
Zeugmann S, Quante A, Popova-Zeugmann L, Kossler W, Heuser I, Anghelescu I: Pathways linking early life stress, metabolic syndrome, and the inflammatory marker fibrinogen in depressed inpatients. Psychiatr Danub 2012;24:57-65.
116.
Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Dow S, Zamkoff J, Dubbert BK, Lougee L: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998;155:264-271.
117.
Riedel M, Straube A, Schwarz MJ, Wilske B, Müller N: Lyme disease presenting as Tourette's syndrome. Lancet 1998;351:418-419.
118.
Müller N, Riedel M, Forderreuther S, Blendinger C, Abele-Horn M: Tourette's syndrome and mycoplasma pneumoniae infection. Am J Psychiatry 2000;157:481-482.
119.
Müller N, Riedel M, Blendinger C, Oberle K, Jacobs E, Abele-Horn M: Mycoplasma pneumoniae infection and Tourette's syndrome. Psychiatry Res 2004;129:119-125.
120.
Allen AJ, Leonard HL, Swedo SE: Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995;34:307-311.
121.
Macerollo A, Martino D: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an evolving concept. Tremor Other Hyperkinet Mov (N Y). 2013 Sep 25;3. pii: tre-03-167-4158-7.
122.
Macerollo A, Martino D: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an evolving concept. Tremor Other Hyperkinet Mov (N Y) 2013;3: pii: tre-03-167-4158-7.
123.
Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999;354:1153-1158.
124.
Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995;29:141-152.
125.
Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P: Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003;19:183-188.
126.
Müller N, Schwarz MJ, Riedel M: COX-2 inhibition in schizophrenia; in Eaton WW (ed): Medical and Psychiatric Comorbidity over the Course of Life. Washington, American Psychiatric Publishing, 2006, pp 265-276.
127.
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011;168:1303-1310.

Send Email

Recipient(s) will receive an email with a link to 'Comorbidity of Mental and Physical Disorders > 99 - 113: Infectious Diseases and Mental Health' and will not need an account to access the content.

Subject: Comorbidity of Mental and Physical Disorders > 99 - 113: Infectious Diseases and Mental Health

(Optional message may have a maximum of 1000 characters.)

×
Close Modal

or Create an Account

Close Modal
Close Modal